Phase 4 Migraine Trial, Recruiting (NCT07609914)

Phase 4 Migraine Trial, Recruiting NCT07609914 Sponsor: Pfizer Condition: Migraine

Printed from Voxsanity (voxsanity.com.au) — NCT07609914 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Migraine

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older who have had migraines (with or without aura) for at least 1 year, diagnosed according to standard international headache guidelines
People who are currently using an approved acute migraine treatment, and who have had an average of 6 to 14 migraine days per month, fewer than 15 total headache days per month, and fewer than 7 non-migraine headache days per month — both in the 12 weeks before the screening visit and during the first 28 days of the observation period

Who may not be able to join:

People who have had 15 or more headache days per month on average (whether migraine or non-migraine) in the 12 weeks before the screening visit
People who have had 7 or more non-migraine headache days per month on average in the 12 weeks before the screening visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07609914

Sponsor: Pfizer

Phase: Phase 4

Status: Recruiting

Condition: Migraine

Trial contact: 1-800-718-1021

More information: https://clinicaltrials.gov/study/NCT07609914

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older who have had migraines (with or without aura) for at least 1 year, diagnosed according to standard international headache guidelines
People who are currently using an approved acute migraine treatment, and who have had an average of 6 to 14 migraine days per month, fewer than 15 total headache days per month, and fewer than 7 non-migraine headache days per month — both in the 12 weeks before the screening visit and during the first 28 days of the observation period

Who may not be able to join:

People who have had 15 or more headache days per month on average (whether migraine or non-migraine) in the 12 weeks before the screening visit
People who have had 7 or more non-migraine headache days per month on average in the 12 weeks before the screening visit

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Pfizer

Registry

ClinicalTrials.gov

Start date

28 May 2026

Est. completion

15 May 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overall; Incidence of LFT elevations, AST >3x ULN, alanine aminotransferase ALT >3x ULN, and total bilirubin >2x ULN on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overall

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov